Member Info for inanaco

Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
Michael D. Crowther, Garry Dolton, Mateusz Legut, Marine E. Caillaud, Angharad Lloyd, Meriem Attaf, Sarah A. E. Galloway, Cristina Rius, Colin P. Farrell, Barbara Szomolay, Ann Ager, Alan L. Parker, Anna Fuller, Marco Donia, James McCluskey, Jamie Rossjohn, Inge Marie Svane, John D. Phillips & Andrew K. Sewell

https://elifesciences.org/articles/24476

found his published work ...

cant really see any difference ....

and he has not as i can find published his work

and i cannot find his published work ..

sorry

did you read the link i posted earlier ... i think that this RESEARCH ARTICLE dated May 18, 2017 which is published and has already identified this "new T cell" and the links to cancer, it does not carry this Cardiff Prof Name of Andew Sewell .. and he has not as i can find published his work ... as a Discovery ... so May 2017 beats him ..

these guys have

Marco Lepore, Artem Kalinichenko, Salvatore Calogero, Pavanish Kumar, Bhairav Paleja, Mathias Schmaler, Vipin Narang, Francesca Zolezzi, Michael Poidinger, Lucia Mori, Gennaro De Libero

https://elifesciences.org/articles/24476

early days

https://elifesciences.org/articles/24476

this group in Switzerland have also seen this MR1

how effective ? no idea to early to say, as we all know .. talk in the lab to clinical trial is a long procedure

Just a quick one ............ ref "binding" of moditope has to be superior ie High Avidity other wise they don't activate .. this is why Scancell is seeing these Potent Killers once activated ie ... very high Binding .. as the reverse happens when they engage

"""""We have identified a new distinct population of mature CD4 T cells that develop in the thymus: the natural cytotoxic CD4 T lymphocytes. We also established mechanism underlying these process by demonstrating that CD4 CTL needs a strong TCR signal for their differentiation.""""

https://www.jimmunol.org/content/198/1_Supplement/150.9?utm_source=TrendMD&utm_medium=cpc&utm_campaign=J_Immunol_TrendMD_0

I agree Chester ..looks to me like an auction could develop ....

"" This is the third collaboration agreement "evaluating" Scancell's pipeline of anti-TaG mAbs""

Ruck .. Tag Team ..
ATB
i can list more than 10 that have been proved as complete nobs ..

Lets just make this point as Ruck and Bermuda have been show boating ...

Patient has lymphoma one solid tumor grows .... having failed all treatments i suspect Chemo and Car T (not as combo) both of which could leave a Mutant cell that is Chemo resistant and Car T resistant ie No Binding position ...

His Doctors do not know why ... this cancer escaped

Patient thinks its grown quickly so blames his treatment ... Press love it ... and give it a name

Scancell

Patient is given the vaccine and one lesion escapes and grows and is surgically removed clearly the vaccine did not bind

so i post ....

”SCIB1 ""had"" that effect on one patient .” what is the same between the patients ......... ? so that ""Had"" which is factual happened ???????

i did not describe SCIB1 our patient as hyperprogression

The press did .. and the patient ... not his Doctors and they left that as a question mark not a statement of fact ...

Here is a great Statement of Fact on Car T ....... from the ""Accurate"" Bermuda ... Ruck

Bermudashorts

Posted in: SCLP

Posts: 10,445

Price: 7.05

No Opinion

BioNTech02 Jan 2020 22:14
Some very encouraging early preclinical data published by BioNTech today for BNT211 - their CAR-T therapy delivered via mRNA vaccine:-

https://www.globenewswire.com/news-release/2020/01/02/1965843/0/en/BioNTech-Announces-Publication-of-Preclinical-Data-for-First-in-Kind-CAR-T-Cell-Therapy-Approach-Targeting-Solid-Tumors-in-Science.html

Maybe i should post the patent discussion Ruck ... from ADFVN ... that would make that "accuracy" statement look even more ridiculous

Tag Team Drivel ...

ATB

TF ... unfortunately that patient has failed all treatment ...

his doctors did not agree with that ...........

he suggested ... ATB

just to help you along Ruck

The thread Title

is that a question mark ........... ?

Immonotherapy worsens cancer ?

oh yea

already explained ...

Seems Bermuda has understood

CAR T-Cell Therapy for Lymphoma
CAR T-cell therapy is a promising treatment for some patients with aggressive non-Hodgkin lymphoma (NHL) that has not responded to other therapies (refractory). It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer. The FDA has approved two CAR T-cell therapies for lymphoma: Yescarta™ and Kymriah™. Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) is one of the first centers to make the FDA-approved therapies available as standard of care to patients who have not had effective treatment options.

Yescarta (also referred to as axicabtagene ciloleucel) is approved for aggressive, relapsed and/or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. The clinical trials of Yescarta showed the therapy to be highly effective with 82 percent of patients responding to the CAR T-cell therapy, including 54 percent who had a complete response (i.e., no sign of cancer). The most recent follow-up data shows that at a median 15.4 months after treatment, 40 percent of patients remain in complete remission, showing the lasting effectiveness of this therapy.
Kymriah (also referred to as tisagenlecleucel) is approved for patients with relapsed or refractory (r/r) large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In clinical trials, patients had strong responses from this therapy: 53 percent responded to treatment, with 40 percent achieving a complete response (i.e. no sign of cancer). Kymriah is also approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) up to age 25. Learn more about Kymriah for pediatric B-cell ALL.

let me think now ... does the press sensationalise an article ..

Maybe

so to explain ... ‘I asked my doctors, “Why is this happening to me?” They didn’t know.

in which case the same effect was seen in Scancells patient, it was not until they surgically removed the lesion did they discover this particular Met was in effect immune from the vaccine ...

so .... the Doctors did NOT describe the patient in the article ..as Hyperprogression ...

made be you can explain how you managed to do that ? as I did not

I think you should read the article ..

""But some doctors doubt that hyperprogression even exists, arguing that these patients would possibly have deteriorated rapidly, regardless of what treatment they had ""

‘I asked my doctors, “Why is this happening to me?” They didn’t know. I understand that my lymphoma was very aggressive from the start, but since having CAR-T, it’s just got so bad, so quickly. From where I’m sitting, it looks like the treatment made me worse.’

Of course, the cancer may have progressed this way, regardless of what treatment he had. But could he be right?

Hope its as rapid as the English Bowlers ....

SCIB1 had that effect on one patient .... one particular Met developed which turned out to be immune from the vaccine, it was surgically removed ..

This is actually the beauty of moditope ... because its not targeting a mutation, its targeting a Cells tool box to survive which is what the immune system is designed to do ie .. look for stressed cells

you need to trust your CD4 T cells ....... Lindy does

is it that Great Knowlesi ?

https://www.bloomberg.com/news/articles/2020-01-14/bankers-paying-2-000-a-night-bemoan-san-francisco-squalor